Zacks: Brokerages Expect Vistagen Therapeutics Inc (NASDAQ:VTGN) Will Post Earnings of -$0.07 Per Share

Wall Street brokerages predict that Vistagen Therapeutics Inc (NASDAQ:VTGN) will post ($0.07) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics reported earnings of ($0.24) per share in the same quarter last year, which would indicate a positive year over year growth rate of 70.8%. The company is expected to announce its next earnings results on Tuesday, February 11th.

According to Zacks, analysts expect that Vistagen Therapeutics will report full year earnings of ($0.40) per share for the current financial year. For the next year, analysts expect that the company will report earnings of ($0.35) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Vistagen Therapeutics.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01.

VTGN has been the subject of a number of recent analyst reports. Maxim Group set a $4.00 price objective on Vistagen Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 15th. ValuEngine downgraded Vistagen Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 27th. Chardan Capital reaffirmed a “neutral” rating on shares of Vistagen Therapeutics in a research report on Monday, December 2nd. Finally, William Blair downgraded Vistagen Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 14th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $2.35.

Institutional investors have recently made changes to their positions in the company. LPL Financial LLC acquired a new position in shares of Vistagen Therapeutics during the second quarter worth about $27,000. Wells Fargo & Company MN acquired a new position in shares of Vistagen Therapeutics during the second quarter worth about $31,000. Virtu Financial LLC acquired a new position in shares of Vistagen Therapeutics during the third quarter worth about $65,000. D.A. Davidson & CO. grew its position in shares of Vistagen Therapeutics by 27.3% during the third quarter. D.A. Davidson & CO. now owns 105,000 shares of the company’s stock worth $112,000 after buying an additional 22,500 shares in the last quarter. Finally, HighTower Advisors LLC grew its position in shares of Vistagen Therapeutics by 326.3% during the second quarter. HighTower Advisors LLC now owns 132,353 shares of the company’s stock worth $96,000 after buying an additional 101,308 shares in the last quarter. 8.75% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ VTGN remained flat at $$0.68 during trading on Friday. The stock had a trading volume of 1,100 shares, compared to its average volume of 477,915. Vistagen Therapeutics has a fifty-two week low of $0.29 and a fifty-two week high of $1.86. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.14 and a quick ratio of 1.14. The company’s 50-day moving average is $0.65 and its two-hundred day moving average is $0.77. The stock has a market cap of $28.54 million, a price-to-earnings ratio of -0.76 and a beta of -0.41.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: Analyst Ratings Trading

Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.